Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On February 27, 2020, Jon Wigginton, M.D., Senior Vice President, Clinical Development and Chief Medical Officer of MacroGenics, Inc. (the "Company"), notified the Company of his resignation, effective March 27, 2020. Dr. Wigginton will be leaving the Company to pursue a new opportunity.

While the executive search for a new Chief Medical Officer is ongoing, Ezio Bonvini, M.D., Senior Vice President, Research and Chief Scientific Officer, will assume Dr. Wigginton's responsibilities on an interim basis, including leading clinical development and related functions. Dr. Bonvini joined the Company in June 2003. He was previously with the Food and Drug Administration (FDA) in the Center for Biologics Evaluation and Research (CBER) for 18 years, ultimately serving as Acting Deputy Director, Division of Monoclonal Antibodies. Dr. Bonvini received his M.D. and Specialty Certification in Clinical Hematology from the University of Genoa, School of Medicine.

Item 7.01 Regulation FD Disclosure.

On March 4, 2020, the Company issued a press release (the "Press Release") announcing the resignation of Dr. Wigginton and the appointment of Dr. Bonvini as head of Clinical Development on an interim basis. A copy of the Press Release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.

Exhibit
  No.      Description

  99.1     Press Release, dated March 4, 2020.
104        Cover Page Interactive Data (embedded within the Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses